Our Story so Far

Concluded a pilot study with 151 participants.  Sensitivity 77%, Specificity 71% and Positive Predictive Value 89%

Shares admitted to trading on AIM of the London Stock Exchange (ticker LLAI) raising gross proceeds of GBP17.0m

Granted our CPT code, the first step on the path for commercial reimbursement

Our laboratory awarded accreditation by the College of American Pathologists

Enrolled our first participant in our multi-center clinical validation study

Our laboratory awarded a Clinical Laboratory Evaluation Program (“CLEP”) by the New York State Department of Health

Appointed one of two industry partners to participate in the Boston University – University of California Los Angeles Lung Cancer Biomarker Development Laboratory of the US National Cancer Institute’s Early Detection Research Network (“EDRN”)

Awarded a price of $2,030 for our LungLB test by the Centers for Medicare & Medicaid Services (“CMS”) effective January 1, 2023

Peer-reviewed publication of a cost effectiveness analysis model on LungLB providing evidence the test can be utilised as a cost-effective alternative to the current diagnostic pathway.  A copy can be accessed here.

Completion of our enrollment for our pivotal validation study

LungLB^® study demonstrating high performance published in peer reviewed journal. Click here to learn more.